Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 2,904 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Capsules Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder

NCT02431806
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Levomilnacipran, Fluoxetine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
12 Years to 17 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
48
States / cities
Dothan, Alabama • Tucson, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 1 Interventional

TD-6450 MAD Study in HCV Infected Subjects

NCT02116543
View directory record Official record
Conditions
Hepatitis C, HCV
Interventions
TD-6450, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Not applicable Interventional Results available

Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza

NCT00555893
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
1 Year to 79 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 31, 2026, 10:11 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris

NCT01193764
View directory record Official record
Conditions
Acne
Interventions
100% cocoa powder, gelatin (Gelita)
Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Reducose® on Glycemic Response and Menopausal Symptoms in Perimenopausal Women (CALM-R)

NCT07333885
View directory record Official record
Conditions
Glycemic Response, Menopause Symptoms
Interventions
Reducose® (Mulberry leaf extract), Placebo
Dietary Supplement
Lead sponsor
Phynova Group Ltd
Industry
Eligibility
40 Years to 60 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 10:11 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health

NCT07760506
View directory record Official record
Conditions
Healthy Aging, Inflammaging, Metabolic Health, Quercetin, Coenzyme Q10
Interventions
Quercetin (dietary supplement), Coenzyme Q10, Rice Flour
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
50 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 2 Interventional

A Clinical Trial of STP0404 in Adults With HIV-1 Infection

NCT05869643
View directory record Official record
Conditions
HIV-1-infection
Interventions
Low-dose STP0404 (Pirmitegravir), Medium-dose STP0404 (Pirmitegravir), High-dose STP0404 (Pirmitegravir), Placebo
Drug
Lead sponsor
ST Pharm Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Los Angeles, California • Ft. Pierce, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 2 Interventional Results available

A Study of FMT in Patients With AML Allo HSCT in Recipients

NCT03678493
View directory record Official record
Conditions
Acute Myeloid Leukemia, Allogeneic Hematopoietic Cell Transplantation
Interventions
Fecal Microbiota Transplant (FMT), Placebo
Biological · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ashwagandha Extract for Weight and Stress Management in Overweight and Obese Adults

NCT07215455
View directory record Official record
Conditions
Weight Management, Stress
Interventions
Ashwagandha 300 mg standardized root extract, Identical placebo capsule.
Dietary Supplement · Other
Lead sponsor
SF Research Institute, Inc.
Network
Eligibility
19 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 3 Interventional

Firibastat in Treatment-resistant Hypertension

NCT04277884
View directory record Official record
Conditions
Hypertension
Interventions
Firibastat, Placebo
Drug
Lead sponsor
Quantum Genomics SA
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Huntington Beach, California • Tustin, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Results available

12-week Efficacy of Indacaterol

NCT01072448
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 75 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
62
States / cities
Peoria, Arizona • Pine Bluff, Arkansas • Buena Park, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

NCT00776009
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
8
States / cities
Little Rock, Arkansas • Bradenton, Florida • South Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 31, 2026, 10:11 AM EDT
Active, not recruiting Not applicable Interventional

Electrical Neuromodulation for Modifying Spinal Network Involved in Spasticity

NCT07792616
View directory record Official record
Conditions
Spinal Cord Injuries (Complete and Incomplete), Spinal Cord Injury, Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injuries, Spasticity, Spasm, Muscle Spasticity, Muscle Hypertonia, Muscle Spasm
Interventions
Transcutaneous spinal stimulation at 30 Hz, Transcutaneous spinal stimulation at 75 Hz, Tizanidine, Baclofen, Placebo
Other · Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety Trial of Naproxen Sodium/ Diphenhydramine

NCT01365052
View directory record Official record
Conditions
Pain
Interventions
Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years and older
Enrollment
326 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
19
States / cities
Chandler, Arizona • Mesa, Arizona • Peoria, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 31, 2026, 10:11 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

NCT01857817
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
VT-122, Placebo
Drug
Lead sponsor
Vicus Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Fayetteville, Arkansas • Santa Rosa, California • Parker, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy

NCT00243789
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Pentoxifylline
Drug
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
7 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache

NCT02423408
View directory record Official record
Conditions
Tension-Type Headache
Interventions
TNX-201, Placebo
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
San Jose, California • DeLand, Florida • Stockbridge, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 31, 2026, 10:11 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19

NCT04400890
View directory record Official record
Conditions
COVID-19
Interventions
Resveratrol, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
Marvin McCreary, MD
Other
Eligibility
45 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 2 Interventional

HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)

NCT02013310
View directory record Official record
Conditions
Age-Associated Memory Impairment (AAMI)
Interventions
HT-0712, Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
50 Years to 80 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
16
States / cities
Sun City, Arizona • Long Beach, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 31, 2026, 10:11 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT03817190
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DS107, Placebo
Drug
Lead sponsor
DS Biopharma
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
26
States / cities
Birmingham, Alabama • Huntington Beach, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 31, 2026, 10:11 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia

NCT01268618
View directory record Official record
Conditions
IBS-D and Functional Dyspepsia
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
Sprim Advanced Life Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Duluth, Georgia • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Oct 31, 2026, 10:11 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses

NCT07330674
View directory record Official record
Conditions
Age Related Macular Degeneration (ARMD), AMD - Age-Related Macular Degeneration
Interventions
ABF-101, Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 31, 2026, 10:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder

NCT01972074
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Memantine, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 31, 2026, 10:11 AM EDT
Not listed Phase 2 Interventional

Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR

NCT01364155
View directory record Official record
Conditions
Impaired Glucose Tolerance, Insulin Resistance
Interventions
LIM-0705, Placebo capsules
Drug
Lead sponsor
Limerick BioPharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2011 · Synced Oct 31, 2026, 10:11 AM EDT